高级检索

氟维司群对未成熟小鼠子宫和阴道雌激素受体表达的影响

曲亚坤, 李鑫, 陈婷, 徐颖, 林娜

曲亚坤, 李鑫, 陈婷, 徐颖, 林娜. 氟维司群对未成熟小鼠子宫和阴道雌激素受体表达的影响[J]. 中国药科大学学报, 2016, 47(2): 210-214. DOI: 10.11665/j.issn.1000-5048.20160214
引用本文: 曲亚坤, 李鑫, 陈婷, 徐颖, 林娜. 氟维司群对未成熟小鼠子宫和阴道雌激素受体表达的影响[J]. 中国药科大学学报, 2016, 47(2): 210-214. DOI: 10.11665/j.issn.1000-5048.20160214
shu
QU Yakun, LI Xin, CHEN Ting, XU Ying, LIN Na. Effects of fulvestrant on the estrogen receptor expression in uterus and vagina of immature mice[J]. Journal of China Pharmaceutical University, 2016, 47(2): 210-214. DOI: 10.11665/j.issn.1000-5048.20160214
Citation: QU Yakun, LI Xin, CHEN Ting, XU Ying, LIN Na. Effects of fulvestrant on the estrogen receptor expression in uterus and vagina of immature mice[J]. Journal of China Pharmaceutical University, 2016, 47(2): 210-214. DOI: 10.11665/j.issn.1000-5048.20160214
shu

氟维司群对未成熟小鼠子宫和阴道雌激素受体表达的影响

  • 1.

    首都医科大学中医药学院

  • 2.

    中国中医科学院中药研究所

基金项目: 国家重点基础研究发展计划(“九七三”计划)资助项目(No.2011CB505300,No.2011CB505305)；国家自然科学基金资助项目(No.81573632)

Effects of fulvestrant on the estrogen receptor expression in uterus and vagina of immature mice

摘要

    摘要
  • 摘要: 为观察氟维司群对雌激素效应的作用及其对靶器官中雌激素受体表达的影响，以未成熟小鼠为实验模型，随机分成正常对照组、氟维司群(500 μg/kg，ip)组、17β-雌二醇组(100 μg/kg，ig)和17β-雌二醇+氟维司群(100 μg/kg+500 μg/kg)4组，给药7 d后麻醉取小鼠的子宫和阴道，HE染色法观察其组织形态学变化、免疫组织化学和Western blot技术检测其雌激素受体α(ERα)和雌激素受体β(ERβ)表达的情况。结果显示，氟维司群可明显影响未成熟小鼠子宫和阴道的生长发育和雌激素受体的表达，同时可显著抑制17β-雌二醇的促未成熟小鼠子宫、阴道生长发育以及促雌激素受体表达的作用。提示氟维司群具有抗雌激素样作用，其机制可能与下调靶器官雌激素受体表达有关。
    Abstract: To observe the estrogen-like effects of fulvestrant and its influence on estrogen receptor expression of fulvestrant, this study set control, fulvestrant(500 μg/kg, ip), 17β-estradiol(100 μg/kg, ig)and 17β-estradiol + fulvestrant(100 μg/kg+500 μg/kg)groups. 7 days after dosing, mice were anesthetized; their uterine and vagina were collected. HE method was used to determine morphological changes of the tissues; protein expression levels of estrogen receptor alpha(ERα)and estrogen receptor beta(ERβ)in uterus and vagina were detected by immunohistochemistry and Western blot. The results showed that fulvestrant could obviously influence the growth of the uterus and vagina and expression of estrogen receptor in immature mice. Meanwhile, fulvestrant could significantly inhibit the growth of the uterus and vagina and increase estrogen receptors expression in immature mice. The research showed that fulvestrant has anti-estrogen-like effects, which may be related to the down-regulation of estrogen receptor expression in the target organs.
    • HTML全文
    • 参考文献(14)
  • [1] Zhou ES,Wang S,Dong CE.The progress on the development of selective estrogen receptor down regulator(SERDs)and their molecular biological mechanism[EB/OL].[2013-02-05] .http://www.paper.edu.cn/releasepaper/content/201302-99.
    [2] Zhang Y,Wang JH,Sun H,et al.Effect and safety of fulvestrant in the treatment of patients with receptor-positive metastatic breast cancer[J].China Prac Med(中国实用医药),2014,9(21):1-3.
    [3] Liu KH,Cao RX.The research progression is the resistance to endocrine therapy in breast cancer in vitro[J].J Pract Oncol(实用肿瘤杂志),2015,25(9):494-498.
    [4] Zhang Y.Vascular protective effects and mechanism research of PQS on postmenopausal women with coronary heart disease(西洋参茎叶总皂苷对绝经后女性冠心病患者的血管保护效应及机制研究)[D].Beijing:China Academy of Chinese Medical Sciences,2013.
    [5] Ma XP,Xu Y,Ding J,et al.Effects of estradiol valerate on the estrogen receptor espression in uterus,vagina and mammary gland of ovariectomized rats[J].J China Pharm Univ(中国药科大学学报),2014,45(3):341-345.
    [6] Lu HY,Cai JF,Wang XJ.The research progress of clinical application of fulvestrant[J].J Prac Oncol(实用肿瘤杂志),2012,27(5):562-564.
    [7] Tan WH, Liu W, Guan YM. The research progress is between estrogen receptor subtypes and gynecological tumors[J].Chin J Birth Health Hered(中国优生与遗传杂志),2005,13(6):116-126.
    [8] Zheng ZH,Liu P.Fulvestrant[J].Chin J New Drugs(中国新药杂志),2004,13(1):78-79.
    [9] Jiang H,Wang T,Jiang ZF.Some clinical issues of fulvestrant for the treatment of breast cancer[J].Clin Medica J(临床药物治疗杂志),2012,10(2):9-13.
    [10] Chen M,Zhao PW,Sun LP,et al.The effect of estrogen receptors in gynecological malignancies[J].China Med(中国医药),2015,10(6):926-928.
    [11] Jiang H,Wang T,Zhang SH,et al.Fulvestrant for the treatment of advanced breast cancer after prior aromatase inhibitor therapy[J].China Oncol(中国癌症杂志),2013,23(3):224-228.
    [12] Wu MH,Wang M,Wang W,et al.Combination of fulvestrant and trastuzumab for the treatment of Luminal B(HER-2 positive)advanced breast cancers after prior aromatase inhibitors[J].Chin Clin Oncol(临床肿瘤学杂志),2014,6(19):512-515.
    [13] Agrawal A,Robertson JF,Cheung KL,et al.Biological effects of fulvestrant on estrogen receptor positive human breast cancer:short,medium and long-term effects based on sequential biopsies[J].Int J Cancer,2016,138(1):146-159.
    [14] Quenel-Tueux N, Debled M, Rudewicz J, et al. Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer[J].Brit J Cancer,2015,113(4):585-594.
    • 相关文章
    • 施引文献
    • 资源附件(0)
计量
  • 文章访问数:  967
  • HTML全文浏览量:  1
  • PDF下载量:  3334
  • 被引次数: 0
出版历程
  • 刊出日期:  2016-04-24

目录

摘要
HTML全文
    参考文献(14)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    版权所有：《中国药科大学学报》编辑部苏ICP备05007142号

    地址：江苏省南京市鼓楼区童家巷24号（210009）电话: 025-83271566E-mail: xuebao@cpu.edu.cn

    本系统由 北京仁和汇智信息技术有限公司 开发  百度统计

    访问量：453184

    x 关闭 永久关闭